• Register
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.


Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.


Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma.

MicroRNA-155 (miR-155) is an oncogenic microRNA that regulates several pathways involved in cell division and immunoregulation. It is overexpressed in numerous cancers, is often correlated with poor prognosis, and is thus a key target for future therapies. In this work we show that overexpression of miR-155 in lymphoid tissues results in disseminated lymphoma characterized by a clonal, transplantable pre-B-cell population of neoplastic lymphocytes. Withdrawal of miR-155 in mice with established disease results in rapid regression of lymphadenopathy, in part because of apoptosis of the malignant lymphocytes, demonstrating that these tumors are dependent on miR-155 expression. We show that systemic delivery of antisense peptide nucleic acids encapsulated in unique polymer nanoparticles inhibits miR-155 and slows the growth of these "addicted" pre-B-cell tumors in vivo, suggesting a promising therapeutic option for lymphoma/leukemia.

Pubmed ID: 22685206


  • Babar IA
  • Cheng CJ
  • Booth CJ
  • Liang X
  • Weidhaas JB
  • Saltzman WM
  • Slack FJ


Proceedings of the National Academy of Sciences of the United States of America

Publication Data

June 26, 2012

Associated Grants

  • Agency: NIBIB NIH HHS, Id: R01 EB000487
  • Agency: NHLBI NIH HHS, Id: R01 HL085416

Mesh Terms

  • Animals
  • Apoptosis
  • Base Sequence
  • Blotting, Western
  • DNA Primers
  • Disease Models, Animal
  • Doxycycline
  • Flow Cytometry
  • Lymphoid Tissue
  • Lymphoma
  • Mice
  • MicroRNAs
  • Nanoparticles
  • Polymerase Chain Reaction